



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)
(AIM: HCM)**

Director’s Shareholding

London: Tuesday, 10 June 2008: Chi-Med was informed on 6 June 2008 that Mr Michael Howell, Independent Non-executive Director of Chi-Med, purchased 25,000 ordinary shares of US\$1.00 each in Chi-Med (the “Shares”) at a price of 122p each on 5 June 2008.

Following this purchase, Mr Howell is beneficially interested in 43,000 Shares, representing approximately 0.08% of the current issued share capital of Chi-Med.

Ends

Enquiries

Chi-Med Telephone: +852 2121 8200
Christian Hogg, CEO

Citigate Dewe Rogerson Telephone: +44 (0) 20 7638 9571
Anthony Carlisle +44 (0) 7973 611 888
David Dible +44 (0) 7967 566 919

About Chi-Med

Chi-Med is the holding company of a pharmaceutical and healthcare group focused on traditional Chinese medicine (“TCM”) based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. Chi-Med operates three core business divisions: 1) China Healthcare – the manufacture, distribution and marketing of pharmaceuticals and health supplements in China; 2) Drug R&D – the discovery and global development of novel drug in the oncology and auto-immune therapeutic areas; and 3) Consumer Products – global retailing and distribution consumer health and personal care products derived from TCM and botanical ingredients.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.